Pfizer licensed Macugen(TM) from Eyetech Pharmaceuticals for US$745 M. Macugen(TM) is a Phase III drug used for treating age-related macular degeneration and diabetic macular oedema. Pfizer and Eyetch will co-promote Macugen(TM) in US, while Pfizer will hold the marketing rights for rest of the world.